Patents by Inventor Larry D. Bratton
Larry D. Bratton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240116972Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.Type: ApplicationFiled: November 15, 2023Publication date: April 11, 2024Inventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
-
Patent number: 11858956Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.Type: GrantFiled: December 17, 2021Date of Patent: January 2, 2024Assignees: Southern Research Institute, Oregon Health & Science University, Washington University in St. Louis, Board of Regents, The University of Texas SystemInventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
-
Publication number: 20230138433Abstract: The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: October 26, 2022Publication date: May 4, 2023Inventors: Omar Moukha-Chafiq, Corinne Elizabeth Augelli-Szafran, Rebecca Boohaker, Larry D. Bratton, Marina Fosso Yatchange, Anish K. Vadukoot
-
Publication number: 20220251134Abstract: The present disclosure is concerned with 2,4,7-substituted-7-deaza-2?-deoxy-2?-fluoroarabinosyl nucleoside and nucleotide prodrugs that are capable of inhibiting viral infections and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), human cytomegalovirus (HCMV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), 229E, NL63, OC43, HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using these compouType: ApplicationFiled: June 12, 2020Publication date: August 11, 2022Inventors: Omar Moukha-Chafiq, Larry D. Bratton, Corinne E. Augelli-Szafran, Mark J. Suto
-
Publication number: 20220204545Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.Type: ApplicationFiled: December 17, 2021Publication date: June 30, 2022Inventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
-
Patent number: 7244763Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: GrantFiled: February 6, 2004Date of Patent: July 17, 2007Assignee: Warner Lambert Company LLCInventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 7067538Abstract: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.Type: GrantFiled: May 21, 2003Date of Patent: June 27, 2006Assignee: Warner-Lambert Company, LLCInventors: Larry D. Bratton, Alexander J. Bridges, David T. Connor, Steven R. Miller, Yuntao Song, Kuai-Lin Sun, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6964983Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: GrantFiled: November 2, 2004Date of Patent: November 15, 2005Assignee: Warner-Lambert Company, LLCInventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6939875Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: GrantFiled: November 2, 2004Date of Patent: September 6, 2005Assignee: Warner-Lambert CompanyInventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6875780Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: GrantFiled: January 22, 2003Date of Patent: April 5, 2005Assignee: Warner-Lambert CompanyInventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Publication number: 20040209936Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: ApplicationFiled: February 6, 2004Publication date: October 21, 2004Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
-
Publication number: 20030225158Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: ApplicationFiled: January 22, 2003Publication date: December 4, 2003Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6329392Abstract: The present invention relates to novel substituted piperidine derivatives of the formula stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic diseases including: seasonal rhinitis, allergic rhinitis, and sinusitis.Type: GrantFiled: May 15, 1998Date of Patent: December 11, 2001Assignee: Aventis Pharmaceuticals, Inc.Inventors: Timothy P. Burkholder, Larry D. Bratton, Elizabeth M. Kudlacz, George P. Maynard, John M. Kane, Braulio Santiago
-
Patent number: 6297259Abstract: The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.Type: GrantFiled: June 9, 1999Date of Patent: October 2, 2001Assignee: Aventis Pharmaceuticals Inc.Inventors: George P. Maynard, John M. Kane, Larry D. Bratton, Elizabeth M. Kudlacz
-
Patent number: 6211199Abstract: The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.Type: GrantFiled: December 15, 1997Date of Patent: April 3, 2001Assignee: Aventis Pharmaceuticals Inc.Inventors: John M. Kane, George D. Maynard, Timothy P. Burkholder, Larry D. Bratton, Christopher R. Dalton, Braulio Santiago, Elizabeth M. Kudlacz
-
Patent number: 6194406Abstract: The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.Type: GrantFiled: October 29, 1997Date of Patent: February 27, 2001Assignee: Aventis Pharmaceuticals Inc.Inventors: John M. Kane, George D. Maynard, Timothy P. Burkholder, Larry D. Bratton, Christopher R. Dalton, Elizabeth M. Kudlacz, Braulio Santiago
-
Patent number: 5998439Abstract: The present invention relates to novel substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.Type: GrantFiled: May 15, 1998Date of Patent: December 7, 1999Assignee: Hoescht Marion Roussel, Inc.Inventors: George P. Maynard, John M. Kane, Larry D. Bratton, Elizabeth M. Kudlacz
-
Patent number: 5932571Abstract: The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)?1,4!diazepan-1-yl)-2-(aryl)butyl)b enzamide derivatives of the formula: ##STR1## stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.Type: GrantFiled: March 6, 1998Date of Patent: August 3, 1999Assignee: Hoechst Marion Roussel, Inc.Inventors: George D. Maynard, John M. Kane, Christopher R. Dalton, Braulio Santiago, Elizabeth M. Kudlacz, Larry D. Bratton
-
Patent number: 5730922Abstract: A laminate has at least two layers, at least one of which comprises a polymer having more than one perfluorocyclobutane group. Such polymers impart qualities of environmental or protection, chemical and solvent resistance, hydrolytic stability, lubricity, low dielectric, hydrostatic stability, weatherability, flame resistance, chemical resistance, hydrolytic stability, lubricity, environmental protection, scratch resistance, solvent resistance, surface passivation, water repellancy, lower surface refractive index, lower surface coefficient of friction, fluid barrier properties, oil repellancy, thermal stability, and/or reduced moisture pick-up. Additionally, the coatings are optically clear, easy to apply either neat, in a solvent or otherwise, have relatively low cure temperatures for their temperature resistance, and exhibit insulating and planarizing capabilities.Type: GrantFiled: July 12, 1996Date of Patent: March 24, 1998Assignee: The Dow Chemical CompanyInventors: David A. Babb, W. Frank Richey, Katherine Clement, Edward R. Peterson, Alvin P. Kennedy, Zdravko Jezic, Larry D. Bratton, Eckel Lan, Donald J. Perettie
-
Patent number: RE39916Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: GrantFiled: November 28, 2005Date of Patent: November 6, 2007Assignee: Warner Lambert CompanyInventors: Bruce J. Auerbach, Larry D. Bratton, Gary Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst